OBJECTIVES: We analyzed whether the American Society of Anesthesiology (ASA) classification could be used as a prognostic factor in renal cell carcinoma. METHODS: ASA classification's impact on cancer-specific survival (CSS) and on overall survival in 145 patients submitted to radical or partial nephrectomy was evaluated, and was compared with clinicopathological variables. RESULTS: CSS was influenced by ASA in uni- and multivariate analyses. Five-year CSS was 95.7, 71.1 and 39.8% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.007). The ASA classification influenced the overall survival too (p < 0.001). When 18 patients with metastases were excluded, the CSS was 95.7, 83.9 and 42.9% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.001). ASA 3 patients had ten times more metastases than ASA1 patients and two times more than ASA 2 patients (p = 0.001). ASA 3 patients had fewer incidental tumors (p = 0.043) than ASA 2 and 3 patients. CONCLUSION: In this series, the ASA classification could be used as a prognostic factor in renal cell carcinoma. Copyright 2010 S. Karger AG, Basel.
OBJECTIVES: We analyzed whether the American Society of Anesthesiology (ASA) classification could be used as a prognostic factor in renal cell carcinoma. METHODS:ASA classification's impact on cancer-specific survival (CSS) and on overall survival in 145 patients submitted to radical or partial nephrectomy was evaluated, and was compared with clinicopathological variables. RESULTS:CSS was influenced by ASA in uni- and multivariate analyses. Five-year CSS was 95.7, 71.1 and 39.8% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.007). The ASA classification influenced the overall survival too (p < 0.001). When 18 patients with metastases were excluded, the CSS was 95.7, 83.9 and 42.9% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.001). ASA 3 patients had ten times more metastases than ASA1 patients and two times more than ASA 2 patients (p = 0.001). ASA 3 patients had fewer incidental tumors (p = 0.043) than ASA 2 and 3 patients. CONCLUSION: In this series, the ASA classification could be used as a prognostic factor in renal cell carcinoma. Copyright 2010 S. Karger AG, Basel.
Authors: Wassim M Bazzi; Daniel D Sjoberg; Michael A Feuerstein; Alexandra Maschino; Sweeney Verma; Melanie Bernstein; Matthew F O'Brien; Thomas Jang; William Lowrance; Robert J Motzer; Paul Russo Journal: J Urol Date: 2014-12-15 Impact factor: 7.450
Authors: Thiago Camelo Mourão; Diego Abreu; Gustavo F Carvalhal; Guillermo Gueglio; Walter H da Costa; Vinicius Fernando Calsavara; Luis Meza-Montoya; Rubén G Bengió; Carlos Scorticati; Ricardo Castillejos-Molina; Francisco Rodríguez-Covarrubias; Ana María Autran-Gómez; José Gadu Campos-Salcedo; Alejandro Nolazco; Carlos Ameri; Hamilton Zampolli; Raúl Langenhin; Diego Muguruza; Marcos Tobias Machado; Pablo Mingote; Jorge Clavijo; Lucas Nogueira; Omar Clark; Agustín R Rovegno; Fernando P Secin; Ricardo Decia; Gustavo C Guimarães; Sidney Glina; Oscar Rodríguez-Faba; Joan Palou; Stenio C Zequi Journal: BMC Urol Date: 2020-07-02 Impact factor: 2.264
Authors: Diego Abreu; Gustavo Carvalhal; Guillermo Gueglio; Ignacio Tobia; Patricio Garcia; Alvaro Zuñiga; Luis Meza; Rubén Bengió; Carlos Scorticati; Ricardo Castillejos; Francisco Rodriguez; Ana María Autran; Carmen Gonzales; Jose Gadu; Alejandro Nolazco; Carlos Ameri; Hamilton Zampolli; Raúl Langenhin; Diego Muguruza; Marcos Tobías Machado; Pablo Mingote; Juan Yandian; Jorge Clavijo; Lucas Nogueira; Omar Clark; Fernando Secin; Agustín Rovegno; Ana Vilas; Enrique Barrios; Ricardo Decia; Gustavo Guimarães; Sidney Glina; Sumanta K Pal; Oscar Rodriguez; Joan Palou; Philippe Spiess; Primo N Lara; W Marston Linehan; Antonio Luigi Pastore; Stenio C Zequi Journal: JCO Glob Oncol Date: 2021-05